General
Preferred name
RIFAPENTINE
Synonyms
DL 473 ()
Cyclopentylrifampicin ()
MDL473 ()
Priftin ()
KTC-1 ()
R-77-3 ()
R-773 ()
ANTIBIOTIC DL-473IT ()
MDL 473 ()
Prifitin ()
Rifapentin ()
DL-473 ()
MDL-473 ()
P&D ID
PD009742
CAS
61379-65-5
Tags
natural product
drug
available
Drug Status
investigational
approved
Drug indication
Antibacterial
Macular degeneration
Tuberculosis
Max Phase
Phase 4
First approval
1998
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Rifapentine is a semisynthetic derivative of rifamycin and belongs to the ansamycin group of antibacterial compounds . Rifapentine is on the World Health Organization's Model List of Essential Medicines (link provided in the Classification table, under the Summary tab below) for use as an oral antituberculosis medication. (GtoPdb)
Compound Sets
15
Cayman Chemical Bioactives
20307
ChEMBL Approved Drugs
CHEMBL1660
ChEMBL Drugs
CHEMBL1660
Drug Repurposing Hub
DrugBank
DB01201
DrugBank Approved Drugs
DB01201
DrugMAP
DMCHV4I
DrugMAP Approved Drugs
DMCHV4I
Guide to Pharmacology
12014
MedChem Express Bioactive Compound Library
HY-B0269
NCATS Inxight Approved Drugs
XJM390A33U
Novartis Chemogenetic Library (NIBR MoA Box)
Prestwick Chemical Library
Selleckchem Bioactive Compound Library
Rifapentine(Priftin)
The Spectrum Collection
External IDs
35
Properties
(calculated by RDKit )
Molecular Weight
876.45
Hydrogen Bond Acceptors
15
Hydrogen Bond Donors
6
Rotatable Bonds
5
Ring Count
7
Aromatic Ring Count
2
cLogP
5.65
TPSA
220.15
Fraction CSP3
0.57
Chiral centers
9.0
Largest ring
24.0
QED
0.09
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Member status
member
MOA
DNA-Directed RNA Polymerase Inhibitors
RNA polymerase inhibitor
Indication
tuberculosis
Target
CYP2C8, CYP2C9, CYP3A4
antibiotic
Bacterial
DNA/RNA Synthesis
Therapeutic Class
Antituberculosis Agents
Pathway
Anti-infection
Source data